

TITLE:

Evaluating persistent biases and quality issues in inter-modality image translation studies for neuroradiology: a systematic review

Table of Contents

| | |
|---|-----------|
| <i>Supplementary methods</i> | 2 |
| CLAIM: | 2 |
| PROBAST | 2 |
| Overview:..... | 2 |
| Domain 1. Participants..... | 3 |
| Domain 2. Predictors | 3 |
| Domain 3. Outcome | 3 |
| Domain 4. Analysis | 3 |
| Adherence evaluation | 4 |
| Statistical tests for CLAIM: | 4 |
| Statistical tests for PROBAST:..... | 4 |
| Search criteria: | 5 |
| Scopus | 5 |
| IEEE Xplore | 5 |
| Pubmed..... | 5 |
| R code for Shapiro-Wilk normality test | 6 |
| R code for determining Fisher’s statistic | 6 |
| <i>Supplementary results</i> | 8 |
| <i>Supplementary Tables</i> | 9 |
| Supplementary table 1. CLAIM criteria as used in this study | 9 |
| Supplementary table 2. PROBAST criteria as used in this study | 11 |
| Supplementary table 3. Included studies | 12 |
| Supplementary table 4. Timing of imaging pairs for model training | 16 |
| Supplementary table 5. CLAIM adherence per clinical purpose | 20 |
| Supplementary table 6. CLAIM adherence per criteria excluding conference publications | 21 |
| Supplementary table 7. CLAIM adherence per purpose group | 22 |
| Supplementary table 8. PROBAST adherence results per question | 23 |
| <i>References:</i> | 24 |

Supplementary methods

There are several tools available for evaluating the quality of research studies. For this work, we considered how relevant the tool was for AI and medical imaging, as well as how common the tool was in similar systematic reviews. We considered three tools for our work, CLAIM, QUADAS-2, and PROBAST.

CLAIM is designed for AI studies and imaging studies, so it was included in this work.

QUADAS-2 was found to have significant overlap with PROBAST, our determination of overlapping criteria is shown below. PROBAST was developed more recently and has a more thorough explanation document, as well as deeper analysis of the model analysis, so we chose to use it for our study rather than QUADAS.

Overlap between QUADAS-2 and PROBAST criteria:

| QUADAS-2 criteria | Overlapping PROBAST criteria |
|-------------------|--|
| 1.1 | 1.1 |
| 1.2 | 1.1 |
| 1.3 | 1.2 |
| 2.1 | 3.5 - not relevant for image translation |
| 2.2 | 4.7 - not relevant for image translation |
| 3.1 | Domain 2: Applicability |
| 3.2 | 2.2 - not relevant for AI |
| 4.1 | 3.6 - relevant for time-sensitive analyses |
| 4.2 | 2.1 - not relevant for AI |
| 4.3 | 2.1 - not relevant for AI |
| 4.4 | 4.3 - not relevant for AI |

CLAIM:

Overview:

In general, the approach from Sivanesan, et al. will be followed.

CLAIM is designed specifically for AI studies in medical imaging, so the questions should be relevant to the studies included in this review.

It should be noted that CLAIM is designed based on the STARD criteria for diagnostic studies. Many image-to-image translation models are designed for attenuation correction, radiotherapy planning, MRI-only protocols, and other purposes unrelated to classification tasks. Thus, questions such as CLAIM 14 and 15 are difficult to judge since the work generates an image rather than annotations or a diagnosis. Without image annotations, there is no need for annotation evaluations, so questions 16-18 are not applicable to those studies.

See also supplementary table 1 for detailed judging criteria.

PROBAST

Overview:

PROBAST was extensively designed to evaluate prognostic or diagnostic studies where the patients are provided a treatment and their outcomes are recorded. This is vastly different from AI development research where it is unethical to alter the outcome of a patient until the AI model has been approved by the appropriate regulatory agency. However, several questions posed are relevant to nearly all studies, and these can help differentiate the methods of the researchers.

Thus, a modified PROBAST was used to evaluate if the methods or datasets used in these studies showed risks of bias. Questions were omitted if they are not relevant to AI models or to image generation studies. Below are the criteria all studies were judged using. See also supplementary table 2.

Domain 1. Participants

Question 1.1: Domain 1 examines if the enrolled patients were appropriate for the study. Several aspects of the traditional PROBAST are not applicable to image translation, For our work we considered if the included participants were collected consistently and that there weren't any obvious exclusions that would have gifted the authors a cleaner dataset at the expense of population representation.

Most studies utilized a publicly available dataset. While these are encouraged in AI research, many are not ideal for medical research.¹⁻⁵ It is common to curate data for AI research in a way that alters the demographic and disease ratios,^{1, 2, 4-6} or so that only the cleanest examples of only the target disease are included. However, real patient data can show many conditions at the same time and there may be artifacts from movement or differences in equipment. Further, curated data may have a set prevalence—so the model has enough training data—which may differ wildly from actual population prevalence. This means the model looks great using the training data, but can only perform this well when given images within that prevalence and that rank of image quality. So, the use of public datasets is a source of concern if the target population does not match that of the current study.

Question 1.2: though the inclusion and exclusion criteria are relevant to establish any changes to the prevalence ratio, this information is not explicitly stated in most studies. The importance of including clear inclusion and exclusion criteria is two-fold. If certain images have been excluded such that misrepresents the typical image quality⁴ or the disease or demographic prevalence in the population,⁷ the resultant model will have poor performance on real images.^{2, 4, 8-14} Conversely, it is reasonable to exclude images from AI model development if they may lead to spurious correlations.^{2, 15} Studies which clearly stated their exclusion criteria were rated as low risk of bias.¹⁶

Domain 2. Predictors

This domain is meant to identify human biases (such as knowing the answer before performing the assessment) and bias introduced by using different means to identify or collect the predictors.

In our work, we consider the features of the input image as the predictors, and the output translated image as the outcome. However, the predictors are not being “assessed” in a traditional sense, an AI is identifying the features, then mathematically manipulating them according to rules it made up. Therefore, this entire domain is unlikely to have any bias and was excluded.

Domain 3. Outcome

This domain is designed to identify bias caused by inappropriately defining or assessing the outcome. In our case, the outcome is the generation of the translated image rather than a diagnosis or prognosis. So, again, this domain was excluded.

Questions 3.1 and 3.2 of this domain ask if the person collecting the outcome data did so knowing how much data and in what format it should be collected. Again, this is not applicable to AI studies since the model always outputs the outcome (translated image) according to its algorithm. Similarly, questions 3.4 and 3.6 are not applicable for AI studies.

Questions 3.3 and 3.5 are inappropriate for image translation studies because the outcome is completely dependent on the predictors. In cases where the translated image is used as part of a diagnostic test, question 3 may be applicable, but we have excluded it for the purpose of this review.

Domain 4. Analysis

Domain 4 is designed to assess if the final data was evaluated appropriately to form the resultant model performance measurement. For example, did enough patients have the outcome to create an adequate sample size? Did the researchers utilize p-hacking techniques such as altering the category definitions to fit the results? This domain is the most complex, but also the most relevant to AI model development studies.

Question 4.1 asks if the sample size was appropriate. This question is relevant to AI model development as small test datasets are not sufficient to prove generalizability^{5, 17} or expose any biases or overfitting^{18, 19} that happened during training. There is no standard for either the required number of individuals or the included number of images for multi-section modalities such as MRI. PROBAST recognizes that the necessary number of patients for machine learning studies differs based on model type and purpose, but recommends validation on a test set including more than 100 individuals. Studies with fewer than 100 patients in the test dataset were regarded as at high risk of bias.

A question for future studies is “Is it acceptable to test on thousands of images from one patient and assume similar results will be produced for other patients?” Particularly for MRI and CT models, there may be very few patients,

but thousands of images. It is not yet possible to prove this question, so, we considered the number of patients to be the main determinant here.

Question 4.2 is not appropriate for image translation works and was excluded.

Question 4.3 and 4.4 are not appropriate for AI studies.

Question 4.5 is not appropriate for AI studies since the algorithm is not subject to this problem.

Question 4.6 is not relevant for image translation studies and was excluded.

Question 4.7 addresses model calibration. This is usually calculated for AI models using AUC, the c-index, or sensitivity and specificity, which are not applicable to image translation studies

Question 4.8 asks if the model optimism caused by insufficient data was addressed. PROBAST explicitly states that splitting a single dataset into training and test datasets is not adequate; the authors must test on an external dataset. An external test set shows if the model is robust to typical image variance^{2, 14} and may expose learned biases which can be addressed with further model training. Studies with no external testing data were marked as high risk of bias.

Question 4.9 is not relevant for AI models.

Adherence evaluation

Statistical tests for CLAIM:

In general, the approach from Sivanesan, et al. will be followed.

“Yes” and “N/A” are scored as 1 point, while “No” is 0 points.

The Shapiro-Wilks test was used to confirm normal distribution of CLAIM adherence scores, the two-sample t test was used to compare means and the Wilcoxon rank-sum test was used to compare median scores between manuscripts published in medically-focused vs engineering-focused journals. Fisher’s exact test was used to compare medically-focused versus engineering-focused studies.

Statistical tests for PROBAST:

Each of the 5 possible responses is given a score. As shown in the table below, questions are given zero points for a “no” answer, one point for a “probably no” answer, two points for an “unclear” answer, three points for a “probably yes” answer and four points for a “yes” answer. This gives a total possible total score of 16 for the four questions. We can then use this score to rank studies based on the extent of bias rather than the classification of at risk of bias or not.

| <u>Study adheres to the PROBAST criteria</u> | <u>Points</u> |
|--|---------------|
| Yes | 4 |
| Probably Yes | 3 |
| Unclear | 2 |
| Probably No | 1 |
| <u>No</u> | <u>0</u> |

The Shapiro-Wilks test was used to confirm normal distribution of PROBAST adherence scores, the two-sample t test was used to compare means and the Wilcoxon rank-sum test was used to compare median scores between manuscripts published in medically-focused vs engineering-focused publications. Fisher’s exact test was used to compare medically-focused versus engineering-focused studies.

Statistical significance is defined as $P < .05$.

Search criteria:

We chose our search criteria based on the most commonly used terms and their variants. These terms were based on our inclusion criteria: radiological imaging, image translation using AI.

In the case of IEEE, since there was no filter to ensure medically related studies were returned, we added exclusion criteria to filter out unrelated topics.

Scopus

8/2/2023

(TITLE-ABS-KEY (radiology) OR TITLE-ABS-KEY (radiography) OR TITLE-ABS-KEY (radiograph) OR TITLE-ABS-KEY (computed tomography) OR TITLE-ABS-KEY (CT) OR TITLE-ABS-KEY (MRI) OR TITLE-ABS-KEY (magnetic resonance) OR TITLE-ABS-KEY (positron emission tomography) OR TITLE-ABS-KEY (PET) OR TITLE-ABS-KEY (x-ray)) AND (TITLE-ABS-KEY (pix2pix) OR TITLE-ABS-KEY ("image translation") OR TITLE-ABS-KEY ("generative adversarial network") OR TITLE-ABS-KEY ("generative network") OR TITLE-ABS-KEY ("GAN") OR TITLE-ABS-KEY (" cycleGAN ") OR TITLE-ABS-KEY (" image synthesis ") OR TITLE-ABS-KEY (" image generation ") OR TITLE-ABS-KEY (" image-to-image ")) AND (LIMIT-TO (SUBJAREA , "MEDI"))

IEEE Xplore

8/9

2015 - present

NOT (("Full Text Only": "transducer") OR ("Full Text Only": "face recognition") OR ("Full Text Only": "automotive") OR ("Full Text Only": "defect detect") OR ("Full Text Only": "automobile") OR ("Full Text Only": "transportation") OR ("Full Text Only": "radar") OR ("Full Text Only": "baggage inspection") OR ("Full Text Only": "sonar") OR ("Full Text Only": "remote sensing") OR ("Full Text Only": "suspicious object") OR ("Full Text Only": "addiction") OR ("Full Text Only": "welding") OR ("Full Text Only": "Fourier") OR ("Full Text Only": "solder") OR ("Full Text Only": "antenna") OR ("Full Text Only": "pollution") OR ("Full Text Only": "mobile communication") OR ("Full Text Only": "security") OR ("Full Text Only": "forgery") OR ("Full Text Only": "forensic"))

AND (("Full Text Only": "magnetic resonance") OR ("Full Text Only": "positron emission tomography") OR ("Full Text Only": "computed tomography") OR ("Full Text Only": "PET") OR ("Full Text Only": "MRI") OR ("Full Text Only": "CT") OR ("Full Text Only": "radiograph") OR ("Full Text Only": "x-ray") OR ("Full Text Only": "radiography")) AND (("Full Text Only": "deep learning") OR ("Full Text Only": "AI") OR ("Full Text Only": "artificial intelligence")) AND (("Full Text Only": "image translation") OR ("Full Text Only": "GAN") OR ("Full Text Only": "generative adversarial network") OR ("Full Text Only": "cycleGAN") OR ("Full Text Only": "pix2pix") OR ("Full Text Only": "image generation") OR ("Full Text Only": "image-to-image") OR ("Full Text Only": "image synthesis"))

Pubmed

12/18/2023 1015 results

("Pix2Pix"[All Fields] OR "conditional gan"[All Fields] OR "cGAN"[All Fields] OR "image-to-image"[All Fields] OR "image-to-image"[All Fields] OR "image translation"[All Fields] OR "image synthesis"[All Fields] OR "synthesized image"[All Fields] OR "generative adversarial network"[All Fields] OR "GAN"[All Fields]) AND ("radiology"[All Fields] OR "radiograph"[All Fields] OR "x-ray"[All Fields] OR "radiography"[All Fields] OR "positron emission tomography"[All Fields] OR "PET"[All Fields] OR "MR"[All Fields] OR "magnetic resonance"[All Fields] OR "CT"[All Fields] OR "computed tomography"[All Fields]) AND ("artificial intelligence"[All Fields] OR "AI"[All Fields] OR "machine learning"[All Fields] OR "deep learning"[All Fields]) AND 2010/01/01:2024/12/31[Date - Publication]

R code for Shapiro-Wilk normality test

```
> shapiroResults <- shapiro.test(shapiroInputData)
> cat("Shapiro-Wilk Test:\n")
> cat("Test Statistic =", shapiroResults$statistic, "\n")
> cat("P-value =", shapiroResults$p.value, "\n")
```

R code for determining Fisher's statistic

For CLAIM tables

| | Medically focused | Engineering focused |
|---|----------------------|------------------------|
| Y | | |
| N | | |

```
# Load the readxl package if not already loaded
if (!requireNamespace("readxl", quietly = TRUE)) {
  install.packages("readxl")
  library(readxl)
}

# Specify the directory path where your .xlsx files are located
folder_path <- "/Users/Desktop/"

# List all .xlsx files in the specified folder
xlsx_files <- list.files(path = folder_path, pattern = ".xlsx", full.names = TRUE)

# Create an empty list to store the matrices
matrices <- list()

# Loop through the .xlsx files and read them into matrices
for (file in xlsx_files) {
  # Read the .xlsx file into a data frame
  data <- read_excel(file)

  # Convert the data frame to a matrix
  data_matrix <- as.matrix(data)

  # Assign a name to the matrix (e.g., based on the file name)
  matrix_name <- sub(".xlsx", "", basename(file))

  # Store the matrix in the list
  matrices[[matrix_name]] <- data_matrix
}

# You now have a list of matrices, where each matrix corresponds to a .xlsx file.
# You can access them using matrices[[1]], matrices[[2]], etc.

for (i in 1:length(matrices)) {
  result <- fisher.test(matrices[[i]])
  results_list[[i]] <- result
}
```

```
# Specify the directory and filename where you want to save the CSV file
output_file <- "/Users/Desktop/results.csv"
```

```
# Write the results_list to a CSV file
write.csv(do.call(rbind, results_list), file = output_file, row.names = FALSE)
```

for PROBAST tables:

| | Medically focused | Engineering focused |
|-------------|----------------------|------------------------|
| Y or PY | | |
| U, PN, or N | | |

```
#Import table for each question (four times in this work)
```

```
> library(readxl)
```

```
> Table <- ("Users/Desktop/Table.xlsx")
```

```
#Add row names
```

```
> rownames(Table) = c("Yes", "Probably Yes", "Unclear", "Probably No", "No")
```

```
# Convert table to matrix
```

```
> Matrix1 <- as.matrix(Table)
```

```
#Perform Fisher's Exact test
```

```
> fisher.test(Matrix1,,simulate.p.value = TRUE)
```

Fisher's Exact Test for Count Data with simulated p-value (based on 2000 replicates)

Supplementary results

Analysis results:

Shapiro-Wilk normality test using all data:

CLAIM adherence:

Test Statistic = 0.9758616

P-value = .05841379

The data is normally distributed

Probast adherence

Test Statistic = 0.7777314

P-value < .000001

The data is not normally distributed

Shapiro-Wilk normality test using studies from medically-focused journals

CLAIM adherence:

Test Statistic = 0.9608678

P-value = .04048373

The data is not normally distributed

Probast adherence

Test Statistic = 0.7363182

P-value < .000001

The data is not normally distributed

Shapiro-Wilk normality test using studies from engineering-focused journals

CLAIM adherence:

Test Statistic = 0.937612

P-value = .03507005

The data is not normally distributed

Probast adherence

Test Statistic = 0.8972887

P-value = .0021388

The data is not normally distributed

Supplementary Tables

Supplementary table 1. CLAIM criteria as used in this study

| | | |
|--------------|----|--|
| Title/ | | |
| Abstract | 1 | Is AI, GAN, or deep learning mentioned in the title, abstract, or keywords? (main text only) |
| | 2 | Is there a rational order to the abstract? (main text only) |
| Introduction | 3 | Is background and rationale for the work described? (main text only) |
| | 4 | Is the purpose of the work described? (main text only) |
| | | Do the authors explicitly state that data was prospectively or retrospectively collected? (main text only) |
| Methods | 5 | Is some study goal described in the introduction or methods? (main text only) |
| | 6 | Is the source of the data described? (main text or supplement) |
| | | Do the authors detail which data was eligible, including where it is from and when the exams occurred? (main text or supplement) |
| | 7 | If the authors perform preprocessing of the data, is it described? (main text or supplement) |
| | | Are data subsets used in the study? This refers to preprocessing subsets, not training/validation (main text or supplement) |
| | 8 | Do the authors define the data using terms common for indexing? (main text or supplement) |
| | | Do the authors state that and how data was deidentified or anonymized? (main text or supplement) |
| | 9 | Do the authors state how missing data was handled? (main text or supplement) |
| | | Typically the Ground Truth is the target imaging modality. Do the authors state enough details for replication? (ie: T1 MRI rather than MRI) (main text or supplement) |
| | 10 | N/A if image translation only. Do the authors give reason for this Ground Truth if there are variations within the modality? (ie: manual versus computer-assisted segmentation or T1 MRI rather than T2 MRI) (main text or supplement) |
| | | N/A if image translation only. For segmentation works, are the annotators qualifications listed? (main text or supplement) |
| | 11 | N/A if image translation only. For segmentation works, are the segmentation tools described? (main text or supplement) |
| | | N/A if image translation only. For segmentation works, was the variability described? (main text or supplement) |
| | 12 | Do the authors justify the size of the dataset with sample size calculations anywhere in the text? (main text or supplement) |
| | | Are the training/test dataset partitions described in either patient numbers or proportions? (main text or supplement) |
| | 13 | Do the authors state that the above partitions were on a patient/image/ etc basis? (main text or supplement) |
| | | Is the model described in enough detail that an AI researcher could replicate it? Best is with a figure. (main text or supplement) |
| | 14 | Are the software libraries (python, etc) listed? (main text or supplement) |
| | | Is model parameter initialization described? (main text or supplement) |
| | | Are training details described? Especially hyperparameters and any augmentation used. (main text or supplement) |
| | 15 | Did the authors describe when to stop training? Describing the loss functions is sufficient. If multiple models were developed, how was the best model chosen? (main text or supplement) |
| | | N/A if no ensembling is apparent. If ensembling applied, was the method described? (main text or supplement) |
| | 16 | Do the authors state the metrics they will use in the methods section? (“No” if you have to guess the metrics by looking at the table.) (main text only) |

- 29 Do the authors state how they measured significance (if numerical values were used)? This
can be significance when using p-value or confidence range. (main text or supplement)
- 30 Was there evaluation of robustness of the model? Or were results shown for all participants?
ie: violin plots, geometrical accuracy plots. (main text or supplement)
- 31 Do the authors provide saliency maps, uncertainty maps, or error maps for model
explainability? (main text or supplement)
- 32 Was there an external test dataset? Can be geographic or temporal. (main text only)
- Results 33 Is there a diagram detailing the inclusion and exclusion of participants? (main text or
supplement)
- 34 Are relevant demographics presented for each partition? (main text or supplement)
- 35 Are the performance metrics described in #28 presented? (main text only)
- 36 Are confidence intervals for the performance metrics given? (main text or supplement)
- 37 Is there any evaluation of failed or improperly classified or segmented cases? (main text or
supplement)
- Discussion 38 Are limitations explicitly provided? (main text only)
- 39 Do the authors discuss how this model is clinically valuable? (main text only)
- Other
information 40 Was the study registered? (main text or supplement)
- 41 If there is a separate protocol, is the website or supplementary file described? N/A if no
additional information provided (main text only)
- 42 Are funding sources revealed? (main text only)

Supplementary table 2. PROBABT criteria as used in this study

Domain 1

- 1.1 Was internal data used or a public dataset?
Were there consistent collection methods?
Was there a data collection protocol?
Was the dataset size determined based on reaching statistical significance?
Was the data collection setting described?
Were collection dates described?
Was this a convenience, consecutive, or random sample?
Was the disease/normal distribution consistent with the population at that facility?
Were dataset demographics listed? (at least sex)
Was the disease/normal distribution consistent with the population at that facility?
Were reader/annotator qualifications described? (if applicable)
Was any pre-processing performed? (including cropping and resizing)
Was data anonymized?
Were there methods for handling missing data?
- 1.2 Were inclusion or exclusion criteria appropriate?

Domain 2

Not appropriate for AI

Domain 3

Not appropriate for image translation

Domain 4

- 4.1 Were there enough patients in the test set? (>100)
- 4.2 Not appropriate for image translation
- 4.3 Not appropriate for image translation
- 4.4 Not appropriate for image translation
- 4.5 Not appropriate for AI
- 4.6 Not appropriate for Image translation
- 4.7 Were calibration and discrimination assessed?
Did the authors consider and compensate for model optimism? Especially by use of an
- 4.8 external test.
- 4.9 Not appropriate for AI

Supplementary table 3. Included studies

| First author | Publication year | Translation direction | Clinical purpose | Purpose category | Source journal type |
|----------------------------------|------------------|---|------------------------------|---|---------------------|
| Abu-Srhan A ²⁰ | 2021 | bidirectional MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Amini Amirkolaei H ²¹ | 2022 | bidirectional MRI-CT | No specific clinical purpose | Image translation | Medicine |
| Amini Amirkolaei H ²² | 2022 | bidirectional MR-CT, bidirectional PET-CT | No specific clinical purpose | Image translation | Engineering |
| Anaya E ²³ | 2020 | MRI-CT | Diagnosis | Attenuation correction | Engineering |
| Arabi H ²⁴ | 2019 | MRI-CT | Diagnosis | Attenuation correction | Medicine |
| Armanious K ²⁵ | 2019 | PET-CT | Diagnosis | Attenuation correction | Engineering |
| Armanious K ²⁶ | 2020 | PET-CT | Diagnosis | Attenuation correction | Medicine |
| Bazangani F ²⁷ | 2022 | PET-MR | No specific clinical purpose | Image translation | Engineering |
| Bharti V ²⁸ | 2023 | bidirectional MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Blanc-Durand P ²⁹ | 2019 | MRI-CT | Diagnosis | Attenuation correction | Medicine |
| Bourbonne V ³⁰ | 2021 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Cao G ³¹ | 2021 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Chen X ³² | 2022 | MRI-CT | Segmentation | Segmentation | Engineering |
| Choi H ³³ | 2018 | PET-MR | Diagnosis | Amyloid burden quantification | Medicine |
| Dinkla AM ³⁴ | 2018 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Dovletov G ³⁵ | 2022 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Emami H ³⁶ | 2020 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Emami H ³⁷ | 2018 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Estakhraji SIZ ³⁸ | 2023 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Feng E ³⁹ | 2022 | CT-MRI | Segmentation | Stroke lesion identification | Medicine |
| Garzon G ⁴⁰ | 2022 | CT-MRI | Segmentation | Stroke lesion identification | Engineering |
| Gholamiankhah F ⁴¹ | 2022 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Gong K ¹⁹ | 2018 | MRI-CT | Diagnosis | Attenuation correction | Medicine |
| Gong K ⁴² | 2021 | MRI-CT | Diagnosis | Attenuation correction | Medicine |
| Gu X ⁴³ | 2023 | CT-MRI | Treatment | Radiotherapy planning | Medicine |
| Gu Y ⁴⁴ | 2021 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Gupta D ⁴⁵ | 2019 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Gutierrez A ⁴⁶ | 2022 | bidirectional MRI-CT | Segmentation | Stroke lesion identification | Medicine |
| Han R ⁴⁷ | 2022 | MRI-CT | Registration | Registration | Engineering |
| Han R ⁴⁸ | 2021 | MRI-CT | Registration | Registration | Engineering |
| Han X ⁴⁹ | 2017 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Hashimoto F ⁵⁰ | 2021 | PET-CT | Diagnosis | Attenuation correction | Medicine |

| First author | Publication year | Translation direction | Clinical purpose | Purpose category | Source journal type |
|----------------------------|------------------|-----------------------|------------------------------|---|---------------------|
| Hu S ⁵¹ | 2022 | MRI-PET | Diagnosis | Alzheimer's classification | Engineering |
| Hu S ⁵² | 2019 | MRI-PET | Diagnosis | Diagnosis | Engineering |
| Huo Y ⁵³ | 2019 | CT-MRI | Segmentation | Segmentation | Engineering |
| Hussein R ⁵⁴ | 2022 | MRI-PET | Diagnosis | Diagnosis of several diseases | Engineering |
| Jabbarpour A ⁵⁵ | 2022 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Jang H ⁵⁶ | 2018 | MRI-CT | Diagnosis | Attenuation correction | Medicine |
| Jiao J ⁵⁷ | 2020 | US-MRI | Diagnosis | Diagnosis | Engineering |
| Jin C B ⁵⁸ | 2019 | CT-MRI | Treatment | Radiotherapy planning | Engineering |
| Jin C B ⁵⁹ | 2018 | CT-MRI | Treatment | Radiotherapy planning | Engineering |
| Kazemifar S ⁶⁰ | 2020 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Kazemifar S ⁶¹ | 2019 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Kearney V ⁶² | 2019 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Kläser K ⁶³ | 2021 | MRI-CT | Diagnosis | Attenuation correction | Medicine |
| Kläser K ⁶⁴ | 2021 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Koh H ⁶⁵ | 2022 | MRI-CT | Treatment | Therapy planning | Medicine |
| Koike Y ⁶⁶ | 2019 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Ladefoged CN ⁶⁷ | 2019 | MRI-CT | Diagnosis | Attenuation correction | Medicine |
| Lan H ⁶⁸ | 2021 | MRI-PET | Diagnosis | Diagnosis | Medicine |
| Lei Y ⁶⁹ | 2019 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Lei Y ⁷⁰ | 2019 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Li G ⁷¹ | 2019 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Li W ⁷² | 2020 | CT-MRI | Treatment | Radiotherapy planning | Medicine |
| Li Y ⁷³ | 2020 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Li Y ⁷⁴ | 2020 | bidirectional MRI-CT | No specific clinical purpose | Image translation | Medicine |
| Liu F ⁷⁵ | 2018 | MRI-CT | Diagnosis | Attenuation correction | Medicine |
| Liu F ⁷⁶ | 2019 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Liu H ⁷⁷ | 2021 | MRI-PET | Diagnosis | Amyloid burden quantification | Medicine |
| Liu H ⁷⁸ | 2020 | MRI-PET | Diagnosis | Amyloid burden quantification | Engineering |
| Liu M ⁷⁹ | 2022 | CT-MRI | Treatment | Radiotherapy planning | Engineering |
| Liu X ⁸⁰ | 2021 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Maspero M ⁸¹ | 2020 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Nehra R ⁸² | 2021 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Nepl S ⁸³ | 2019 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Nie D ⁸⁴ | 2017 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Nie D ⁸⁵ | 2018 | MRI-CT | Treatment | Radiotherapy planning | Engineering |

| First author | Publication year | Translation direction | Clinical purpose | Purpose category | Source journal type |
|-------------------------------|------------------|-----------------------|------------------------------|---|---------------------|
| Nijskens L ⁸⁶ | 2023 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Pan Y ⁸⁷ | 2018 | MRI-PET | Diagnosis | Alzheimer's classification | Medicine |
| Prokopenko D ⁸⁸ | 2019 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Qin J ⁸⁹ | 2022 | MRI-PET | Prognosis | MRI-only Glioma management | Medicine |
| Ranjan A ⁹⁰ | 2021 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Reinhold JC ⁹¹ | 2020 | CT-MRI | No specific clinical purpose | Image translation | Engineering |
| Reinhold JC ⁹² | 2020 | CT-MRI | Segmentation | Segmentation | Engineering |
| Rubin J ⁹³ | 2019 | CT-MRI | Segmentation | Stroke lesion identification | Engineering |
| Sanaat A ⁹⁴ | 2021 | MRI-CT | No specific clinical purpose | Image translation | Medicine |
| Shafai-Erfani G ⁹⁵ | 2019 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Singh M ⁹⁶ | 2021 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Soltanpour M ⁹⁷ | 2023 | CT-MRI | Segmentation | Stroke lesion identification | Engineering |
| Spuhler KD ⁹⁸ | 2019 | MRI-PET | Diagnosis | Attenuation correction | Medicine |
| Stimpel B ⁹⁹ | 2019 | MRI-Xray | Treatment | Interventional imaging | Engineering |
| Sun B ¹⁰⁰ | 2022 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Sun H ¹⁰¹ | 2019 | MRI-PET | Diagnosis | Diagnosis | Engineering |
| Takamiya K ¹⁰² | 2023 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Takita H ¹⁰³ | 2023 | MRI-PET | Diagnosis, Prognosis | Diagnosis, Prognosis of glioma | Medicine |
| Tang B ¹² | 2020 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Tao L ¹⁰⁴ | 2020 | MRI-CT | Diagnosis | Attenuation correction | Medicine |
| Wang C ¹⁰⁵ | 2021 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Wang C ¹⁰⁶ | 2022 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Wang CC ¹⁰⁷ | 2022 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Wang J ¹⁰⁸ | 2022 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Wang J ¹⁰⁹ | 2022 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |
| Wang J ¹¹⁰ | 2021 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Wang J ¹¹¹ | 2023 | bidirectional MRI-CT | No specific clinical purpose | Image translation | Medicine |
| Wei W ¹¹² | 2019 | MRI-PET | Diagnosis | MRI-only MS classification | Medicine |
| Wolterink J ¹¹³ | 2017 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Xiang L ¹¹⁴ | 2018 | MRI-CT | Treatment | Radiotherapy planning | Medicine |
| Xu R ¹¹⁵ | 2022 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Yang H ¹¹⁶ | 2020 | MRI-CT | Registration | Registration | Medicine |
| Yang H ¹¹⁷ | 2020 | MRI-CT | Treatment | Radiotherapy planning | Engineering |
| Zhang J ¹¹⁸ | 2022 | MRI-PET | Diagnosis | Alzheimer's classification | Medicine |

| First author | Publication year | Translation direction | Clinical purpose | Purpose category | Source journal type |
|-----------------------|-------------------------|------------------------------|-------------------------|---|----------------------------|
| Zhao S ¹¹⁹ | 2022 | MRI-CT | Treatment | Radiotherapy planning + dose calculations | Medicine |

Supplementary table 4. Timing of imaging pairs for model training

| First author | Clinical purpose | Purpose category | Database name | Case-cohort, consecutive, or case-control sample | Timing between source image and ground truth image |
|---------------------------------|------------------------------|-------------------------------|--|--|--|
| Abu-Srhan A ²⁰ | Treatment | Radiotherapy planning | Han (2017), pooled with internal data | random, unknown | Unclear |
| Amini Amirkolae H ²² | No specific clinical purpose | Image translation | Han (2017) | random | Unclear |
| Amini Amirkolae H ²² | No specific clinical purpose | Image translation | Han (2017) | random | Unclear |
| Anaya E ²³ | Diagnosis | Attenuation correction | internal | cohort | Unclear |
| Arabi H ²⁴ | Diagnosis | Attenuation correction | internal | cohort | Unclear |
| Armanious K ²⁵ | Diagnosis | Attenuation correction | internal | consecutive | Unclear |
| Armanious K ²⁶ | Diagnosis | Attenuation correction | internal | cohort | joint PET/CT scanner (SOMATOM mCT) |
| Bazangani F ²⁷ | No specific clinical purpose | Image translation | ADNI (10/11/2020) | controls taken from database | less than 1 year |
| Bharti V ²⁸ | Treatment | Radiotherapy planning | Al-Kadi (2021) | cohort | N/A |
| Blanc-Durand p ²⁹ | Diagnosis | Attenuation correction | manufacturer's dataset, internal | consecutive | Unclear |
| Bourbonne V ³⁰ | Treatment | Radiotherapy planning | internal | cohort | less than 14 days |
| Cao G ³¹ | Treatment | Radiotherapy planning | internal | cohort | N/A |
| Chen X ³² | Segmentation | Segmentation | CQ500, ADNI | cohort | Unclear |
| Choi H ³³ | Diagnosis | Amyloid burden quantification | ADNI | cohort | Unclear |
| Dinkla AM ³⁴ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Dovletov G ³⁵ | Treatment | Radiotherapy planning | RIRE | cohort | Unclear |
| Emami H ³⁶ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Emami H ³⁷ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Estakhraji SIZ ³⁸ | Treatment | Radiotherapy planning | internal | cohort | within 48 hours |
| Feng E ³⁹ | Segmentation | Stroke lesion identification | ISLES2018 | stroke cohort | within 3 hours |
| Garzon G ⁴⁰ | Segmentation | Stroke lesion identification | ISLES2017 & ISLES2018 for training, testing on iDBMRXFDG | unclear, unclear, healthy cohort | unpaired training, same day for iDBMRXFDG |
| Gholamiank hah F ⁴¹ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Gong K ¹⁹ | Diagnosis | Attenuation correction | internal | healthy cohort | Unclear |
| Gong K ⁴² | Diagnosis | Attenuation correction | internal | healthy cohort | Unclear |
| Gu X ⁴³ | Treatment | Radiotherapy planning | internal | cohort | within 2 weeks |

| First author | Clinical purpose | Purpose category | Database name | Case-cohort, consecutive, or case-control sample | Timing between source image and ground truth image |
|----------------------------|------------------|-------------------------------|---|--|--|
| Gu Y ⁴⁴ | Treatment | Radiotherapy planning | https://brainweb.bic.mni.mcgill.ca/ | cohort | Unclear (all synthetic data) |
| Gupta D ⁴⁵ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Gutierrez A ⁴⁶ | Segmentation | Stroke lesion identification | pooled ESCAPE trial, the I-KNOW study, the INTERRSeCT study, and local datasets from the University Medical Center, Hamburg-Eppendorf | RCT, cohort, cohort, unclear | 2-7 days after symptoms (follow-up imaging), unclear |
| Han R ⁴⁸ | Registration | Registration | internal | cohort | same day |
| Han R ⁴⁷ | Registration | Registration | internal | cohort | same day |
| Han X ⁴⁹ | Treatment | Radiotherapy planning | internal (this is the Han dataset source paper) | random | Unclear |
| Hashimoto F ⁵⁰ | Diagnosis | Attenuation correction | internal | cohort | Unclear |
| Hu S ⁵² | Diagnosis | Diagnosis | ADNI | cohort | Unclear |
| Hu S ⁵¹ | Diagnosis | Alzheimer's classification | ADNI, OASIS-3 for test | cohort | Unclear |
| Huo Y ⁵³ | Segmentation | Segmentation | OASIS | cohort | N/A |
| Hussein R ⁵⁴ | Diagnosis | Diagnosis of several diseases | internal | case-control | simultaneously |
| Jabbarpour A ⁵⁵ | Treatment | Radiotherapy planning | internal | cohort | N/A |
| Jang H ⁵⁶ | Diagnosis | Attenuation correction | internal | cohort | same day |
| Jiao J ⁵⁷ | Diagnosis | Diagnosis | MRI from CRL fetal brain atlas, US from INTERGROWTH-21st project | convenience | N/A |
| Jin C B ⁵⁸ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Jin C B ⁵⁹ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Kazemifar S ⁶⁰ | Treatment | Radiotherapy planning | internal | random, cohort | Unclear |
| Kazemifar S ⁶¹ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Kearney V ⁶² | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Kläser K ⁶³ | Diagnosis | Attenuation correction | internal | cohort | immediately after |
| Kläser K ⁶⁴ | Treatment | Radiotherapy planning | internal | cohort | same day |
| Koh H ⁶⁵ | Treatment | Therapy planning | internal | cohort | Unclear |
| Koike Y ⁶⁶ | Treatment | Radiotherapy planning | TCIA | cohort | Unclear |
| Ladefoged CN ⁶⁷ | Diagnosis | Attenuation correction | internal | cohort | less than 8 months |
| Lan H ⁶⁸ | Diagnosis | Diagnosis | ADNI | random | Unclear |
| Lei Y ⁷⁰ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Lei Y ⁶⁹ | Treatment | Radiotherapy planning | internal | cohort | Unclear |

| First author | Clinical purpose | Purpose category | Database name | Case-cohort, consecutive, or case-control sample | Timing between source image and ground truth image |
|----------------------------|------------------------------|-------------------------------|--|---|--|
| Li G ⁷¹ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Li W ⁷² | Treatment | Radiotherapy planning | internal | unclear | Unclear |
| Li Y ⁷³ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Li Y ⁷⁴ | No specific clinical purpose | Image translation | internal | cohort | Unclear |
| Liu F ⁷⁵ | Diagnosis | Attenuation correction | internal | stroke cohort | same day |
| Liu F ⁷⁶ | Treatment | Radiotherapy planning | internal | stroke cohort for training, cancer cohort for testing | same day |
| Liu H ⁷⁸ | Diagnosis | Amyloid burden quantification | internal | cohort | simultaneously |
| Liu H ⁷⁷ | Diagnosis | Amyloid burden quantification | internal | cohort | simultaneously |
| Liu M ⁷⁹ | Treatment | Radiotherapy planning | SZSPH dataset | unclear | Unclear |
| Liu X ⁸⁰ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Maspero M ⁸¹ | Treatment | Radiotherapy planning | internal | cohort | within 35 days, but one outlier at 521 days |
| Nehra R ⁸² | Treatment | Radiotherapy planning | ADNI | cohort | N/A |
| Neppl S ⁸³ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Nie D ⁸⁴ | Treatment | Radiotherapy planning | ADNI | cohort | Unclear |
| Nie D ⁸⁵ | Treatment | Radiotherapy planning | ADNI | cohort | Unclear |
| Nijskens L ⁸⁶ | Treatment | Radiotherapy planning | internal | cohort | within 1.5 months |
| Pan Y ⁸⁷ | Diagnosis | Alzheimer's classification | ADNI-1 and ADNI-2 | cohort | Unclear |
| Prokopenko D ⁸⁸ | Treatment | Radiotherapy planning | TCIA CPTAC, Head-and-neck cancer dataset, internal (internal split for train and test) | cohort | N/A |
| Qin J ⁸⁹ | Prognosis | MRI-only Glioma management | TCIA ACRIN-FMISO-Brain | cohort | 1-7 days |
| Ranjan A ⁹⁰ | Treatment | Radiotherapy planning | Atlas project | cohort | 1-5 days |
| Reinhold JC ⁹¹ | No specific clinical purpose | Image translation | internal | healthy cohort | Unclear |
| Reinhold JC ⁹² | Segmentation | Segmentation | internal | healthy cohort | Unclear |
| Rubin J ⁹³ | Segmentation | Stroke lesion identification | ISLES2018 | stroke cohort | within 3 hours |
| Sanaat A ⁹⁴ | No specific clinical purpose | Image translation | internal | cohort | Unclear |

| First author | Clinical purpose | Purpose category | Database name | Case-cohort, consecutive, or case-control sample | Timing between source image and ground truth image |
|-------------------------------|------------------------------|--------------------------------|-------------------------------------|--|---|
| Shafai-Erfani G ⁹⁵ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Singh M ⁹⁶ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Soltanpour M ⁹⁷ | Segmentation | Stroke lesion identification | internal | cohort | Unclear |
| Spuhler KD ⁹⁸ | Diagnosis | Attenuation correction | internal | cohort | Unclear |
| Stimpel B ⁹⁹ | Treatment | Interventional imaging | internal | cohort | Unclear |
| Sun B ¹⁰⁰ | Treatment | Radiotherapy planning | ABCs MICCAI 2020 challenge dataset | cohort | N/A |
| Sun H ¹⁰¹ | Diagnosis | Diagnosis | ADNI | cohort | similar dates |
| Takamiya K ¹⁰² | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Takita H ¹⁰³ | Diagnosis, Prognosis | Diagnosis, Prognosis of glioma | internal, TCIA | cohort | within 1 month |
| Tang B ¹² | Treatment | Radiotherapy planning | internal | cohort | same day |
| Tao L ¹⁰⁴ | Diagnosis | Attenuation correction | internal | cohort | Unclear |
| Wang C ¹⁰⁵ | Treatment | Radiotherapy planning | internal | cohort | same day for initial CT, 3 days or less for replanning CT |
| Wang C ¹⁰⁶ | Treatment | Radiotherapy planning | internal | cohort | same day for initial CT, 3 days or less for replanning CT |
| Wang CC ¹⁰⁷ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Wang J ¹⁰⁸ | Treatment | Radiotherapy planning | internal | cohort | less than 2 days |
| Wang J ¹⁰⁹ | Treatment | Radiotherapy planning | internal | cohort | N/A |
| Wang J ¹¹⁰ | Treatment | Radiotherapy planning | internal | cohort | less than one month |
| Wang J ¹¹¹ | No specific clinical purpose | Image translation | Han (2017) | selected cohort of 1/3 of dataset | Unclear |
| Wei W ¹¹² | Diagnosis | MRI-only MS classification | internal | age-matched case-control | Unclear |
| Wolterink J ¹¹³ | Treatment | Radiotherapy planning | internal | cohort | same day |
| Xiang L ¹¹⁴ | Treatment | Radiotherapy planning | ADNI | cohort | Unclear |
| Xu R ¹¹⁵ | Treatment | Radiotherapy planning | internal | cohort | N/A |
| Yang H ¹¹⁶ | Registration | Registration | internal | healthy cohort | Unclear |
| Yang H ¹¹⁷ | Treatment | Radiotherapy planning | internal | cohort | Unclear |
| Zhang J ¹¹⁸ | Diagnosis | Alzheimer's classification | ADNI | cohort | Unclear |
| Zhao S ¹¹⁹ | Treatment | Radiotherapy planning | internal, model pre-trained on RIRE | cohort | within 1 week |

Supplementary table 5. CLAIM adherence per clinical purpose

| Clinical purpose | Medicine | | Engineering | |
|------------------------------|-----------------|--------------------|--------------------|--------------------|
| | N | CLAIM score | N | CLAIM score |
| Diagnosis | 19 | 75% | 8 | 69% |
| Prognosis | 2 | 74% | 0 | |
| Registration | 1 | 67% | 2 | 75% |
| Segmentation | 2 | 69% | 6 | 58% |
| Treatment | 37 | 73% | 19 | 63% |
| No specific clinical purpose | 4 | 70% | 3 | 65% |

N: number of studies.

Supplementary table 6. CLAIM adherence per criteria excluding conference publications

| | Criteria | Medically-focused Journal publications (N=61) | | | | Engineering-focused Journal publications (N=11) | | | | P-value | |
|------------------|----------|---|----|-----|-------------|---|----|-----|-------------|---------------|---------------|
| | | Yes | No | N/A | % adherence | Yes | No | N/A | % adherence | | |
| TITLE / ABSTRACT | 1 | 60 | 1 | 0 | 98% | 9 | 2 | 0 | 82% | 0.0590 | |
| | 2 | 61 | 0 | 0 | 100% | 11 | 0 | 0 | 100% | 1.0000 | |
| INTRO- DUCTION | 3 | 61 | 0 | 0 | 100% | 11 | 0 | 0 | 100% | 1.0000 | |
| | 4 | 61 | 0 | 0 | 100% | 11 | 0 | 0 | 100% | 1.0000 | |
| METHODS | 5 | 19 | 42 | 0 | 31% | 0 | 11 | 0 | 0% | 0.0307 | |
| | 6 | 61 | 0 | 0 | 100% | 11 | 0 | 0 | 100% | 1.0000 | |
| | 7 | 61 | 0 | 0 | 100% | 10 | 1 | 0 | 91% | 0.1528 | |
| | 8 | 20 | 41 | 0 | 33% | 0 | 11 | 0 | 0% | 0.0279 | |
| | 9 | 55 | 6 | 0 | 90% | 9 | 2 | 0 | 82% | 0.5990 | |
| | 10 | 10 | 0 | 51 | 100% | 0 | 0 | 11 | 100% | 1.0000 | |
| | 11 | 60 | 1 | 0 | 98% | 10 | 1 | 0 | 91% | 0.2840 | |
| | 12 | 5 | 56 | 0 | 8% | 0 | 11 | 0 | 0% | 1.0000 | |
| | 13 | 4 | 57 | 0 | 7% | 0 | 11 | 0 | 0% | 1.0000 | |
| | 14 | 61 | 0 | 0 | 100% | 11 | 0 | 0 | 100% | 1.0000 | |
| | 15 | 8 | 0 | 53 | 100% | 0 | 0 | 11 | 100% | 1.0000 | |
| | 16 | 3 | 6 | 52 | 90% | 0 | 0 | 11 | 100% | 0.5812 | |
| | 17 | 7 | 2 | 52 | 97% | 0 | 0 | 11 | 100% | 1.0000 | |
| | 18 | 1 | 8 | 52 | 87% | 0 | 0 | 11 | 100% | 0.3439 | |
| | 19 | 1 | 60 | 0 | 2% | 0 | 11 | 0 | 0% | 1.0000 | |
| | 20 | 59 | 1 | 1 | 98% | 10 | 1 | 0 | 91% | 0.2840 | |
| | 21 | 53 | 7 | 1 | 89% | 8 | 3 | 0 | 73% | 0.1740 | |
| | 22 | 60 | 1 | 0 | 98% | 11 | 0 | 0 | 100% | 1.0000 | |
| | 23 | 48 | 13 | 0 | 79% | 7 | 4 | 0 | 64% | 0.2754 | |
| | 24 | 29 | 32 | 0 | 48% | 8 | 3 | 0 | 73% | 0.1909 | |
| | 25 | 53 | 7 | 1 | 89% | 11 | 0 | 0 | 100% | 0.5854 | |
| | 26 | 58 | 3 | 1 | 95% | 11 | 0 | 0 | 100% | 1.0000 | |
| | 27 | 0 | 0 | 61 | 100% | 0 | 0 | 11 | 100% | 1.0000 | |
| | 28 | 58 | 3 | 0 | 95% | 11 | 0 | 0 | 100% | 1.0000 | |
| | 29 | 36 | 25 | 0 | 59% | 3 | 8 | 0 | 27% | 0.0972 | |
| | 30 | 25 | 36 | 0 | 41% | 3 | 8 | 0 | 27% | 0.5108 | |
| | 31 | 43 | 18 | 0 | 70% | 8 | 3 | 0 | 73% | 1.0000 | |
| | 32 | 6 | 55 | 0 | 10% | 0 | 11 | 0 | 0% | 0.5812 | |
| | RESULTS | 33 | 2 | 59 | 0 | 3% | 0 | 11 | 0 | 0% | 1.0000 |
| | | 34 | 21 | 40 | 0 | 34% | 0 | 11 | 0 | 0% | 0.0269 |
| | | 35 | 61 | 0 | 0 | 100% | 11 | 0 | 0 | 100% | 1.0000 |
| | | 36 | 6 | 1 | 54 | 98% | 0 | 0 | 11 | 100% | 1.0000 |
| 37 | | 19 | 42 | 0 | 31% | 1 | 10 | 0 | 9% | 0.2704 | |
| DISCUSSION | 38 | 33 | 28 | 0 | 54% | 4 | 7 | 0 | 36% | 0.3378 | |
| | 39 | 57 | 4 | 0 | 93% | 9 | 2 | 0 | 82% | 0.2258 | |
| OTHER | 40 | 2 | 4 | 55 | 93% | 0 | 1 | 10 | 91% | 0.5748 | |
| | 41 | 26 | 0 | 35 | 100% | 4 | 0 | 7 | 100% | 1.0000 | |
| | 42 | 47 | 14 | 0 | 77% | 10 | 1 | 0 | 91% | 0.4387 | |

Bold indicates significance.

Supplementary table 7. CLAIM adherence per purpose group

| Purpose group | Medicine | | Engineering | |
|--------------------------------|----------|-------------|-------------|-------------|
| | N | CLAIM score | N | CLAIM score |
| Alzheimer's classification | 2 | 0.655 | 2 | 0.750 |
| Attenuation correction | 12 | 0.752 | 2 | 0.655 |
| CT-based radiotherapy planning | 0 | | 3 | 0.667 |
| MRI-only Glioma management | 2 | 0.762 | 0 | |
| MRI-only MS classification | 1 | 0.833 | 0 | |
| MRI-only radiotherapy planning | 34 | 0.737 | 15 | 0.627 |
| Other | 10 | 0.712 | 8 | 0.667 |
| Registration | 1 | 0.667 | 2 | 0.750 |
| Segmentation | 0 | | 3 | 0.659 |
| Stroke lesion identification | 2 | 0.690 | 3 | 0.508 |

N: number of studies. MS: Multiple sclerosis

Supplementary table 8. PROBAST adherence results per question

| PROBAST question | % Yes or Probably Yes (low risk of bias) | | |
|---------------------|--|-------------------------|--------------|
| | Medically- focused | Engineering- focused | P-value |
| | (N=64) | (N=38) | |
| 1.1 | 100% | 87% | 0.006 |
| 1.2 | 28% | 13% | 0.0919 |
| 4.1 | 11% | 5% | 0.4781 |
| 4.8 | 13% | 3% | 0.1482 |

References:

1. Colak E, Kitamura FC, Hobbs SB, et al. The RSNA Pulmonary Embolism CT Dataset. *Radiol Artif Intell* 2021;3:e200254. DOI: 10.1148/ryai.2021200254
2. Liang W, Tadesse GA, Ho D, et al. Advances, challenges and opportunities in creating data for trustworthy AI. *Nature Machine Intelligence* 2022;4:669-677. DOI: 10.1038/s42256-022-00516-1
3. Soffer S, Ben-Cohen A, Shimon O, et al. Convolutional Neural Networks for Radiologic Images: A Radiologist's Guide. *Radiology* 2019;290:590-606. DOI: 10.1148/radiol.2018180547
4. Wahid KA, Gleean E, Sahlsten J, et al. Artificial Intelligence for Radiation Oncology Applications Using Public Datasets. *Semin Radiat Oncol* 2022;32:400-414. DOI: 10.1016/j.semradonc.2022.06.009
5. Willemink MJ, Koszek WA, Hardell C, et al. Preparing Medical Imaging Data for Machine Learning. *Radiology* 2020;295:4-15. DOI: 10.1148/radiol.2020192224
6. Daneshjou R, Smith MP, Sun MD, et al. Lack of Transparency and Potential Bias in Artificial Intelligence Data Sets and Algorithms: A Scoping Review. *JAMA Dermatol* 2021;157:1362-1369. DOI: 10.1001/jamadermatol.2021.3129
7. Khan SM, Liu X, Nath S, et al. A global review of publicly available datasets for ophthalmological imaging: barriers to access, usability, and generalisability. *Lancet Digit Health* 2021;3:e51-e66. DOI: 10.1016/S2589-7500(20)30240-5
8. Holla B, Taylor PA, Glen DR, et al. A series of five population-specific Indian brain templates and atlases spanning ages 6-60 years. *Hum Brain Mapp* 2020;41:5164-5175. DOI: 10.1002/hbm.25182
9. Rao NP, Jeelani H, Achalia R, et al. Population differences in brain morphology: Need for population specific brain template. *Psychiatry Res Neuroimaging* 2017;265:1-8. DOI: 10.1016/j.psychres.2017.03.018
10. Rushmore RJ, Sunderland K, Carrington H, et al. Anatomically curated segmentation of human subcortical structures in high resolution magnetic resonance imaging: An open science approach. *Front Neuroanat* 2022;16:894606. DOI: 10.3389/fnana.2022.894606
11. Sivaswamy J, Thottupattu AJ, Mehta R, et al. Construction of Indian human brain atlas. *Neurol India* 2019;67:229-234. DOI: 10.4103/0028-3886.253639
12. Tang B, Wu F, Fu Y, et al. Dosimetric evaluation of synthetic CT image generated using a neural network for MR-only brain radiotherapy. *Journal of Applied Clinical Medical Physics* 2021;22:55-62. DOI: 10.1002/acm2.13176
13. Wu J, Sun T, Yu B, et al. Age-specific structural fetal brain atlases construction and cortical development quantification for chinese population. *Neuroimage* 2021;241:118412. DOI: 10.1016/j.neuroimage.2021.118412
14. Zech JR, Badgeley MA, Liu M, et al. Variable generalization performance of a deep learning model to detect pneumonia in chest radiographs: A cross-sectional study. *PLoS Med* 2018;15:e1002683. DOI: 10.1371/journal.pmed.1002683
15. Nagarajan V, Andreassen A, Neyshabur B. Understanding the failure modes of out-of-distribution generalization. *arXiv preprint arXiv:201015775* 2020DOI: 10.48550/arXiv.2010.15775
16. Moons KG, Wolff RF, Riley RD, et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. *Annals of internal medicine* 2019;170:W1-W33. DOI: 10.7326/M18-1377
17. Park SH, Han K. Methodologic Guide for Evaluating Clinical Performance and Effect of Artificial Intelligence Technology for Medical Diagnosis and Prediction. *Radiology* 2018;286:800-809. DOI: 10.1148/radiol.2017171920
18. Decuyper M, Maebe J, Van Holen R, et al. Artificial intelligence with deep learning in nuclear medicine and radiology. *EJNMMI Physics* 2021;8:81. DOI: 10.1186/s40658-021-00426-y
19. Gong K, Yang J, Kim K, et al. Attenuation correction for brain PET imaging using deep neural network based on Dixon and ZTE MR images. *Phys Med Biol* 2018;63:125011. DOI: 10.1088/1361-6560/aac763
20. Abu-Srhan A, Almallahi I, Abushariah MA, et al. Paired-unpaired Unsupervised Attention Guided GAN with transfer learning for bidirectional brain MR-CT synthesis. *Computers in Biology and Medicine* 2021;136:104763. DOI: 10.1016/j.compbiomed.2021.104763
21. Amirkolaei HA, Amirkolaei HA. Medical image translation using an edge-guided generative adversarial network with global-to-local feature fusion. *Journal of Biomedical Research* 2022;36:409. DOI: 10.7555/JBR.36.20220037
22. Amini Amirkolaei H, Olegovich Bokov D, Sharma H. Development of a GAN architecture based on integrating global and local information for paired and unpaired medical image translation. 2022DOI: 10.1016/j.eswa.2022.117421

23. Anaya E, Levin C. Automatic Generation of MR-based Attenuation Map using Conditional Generative Adversarial Network for Attenuation Correction in PET/MR. *2020 IEEE Nuclear Science Symposium and Medical Imaging Conference (NSS/MIC)*: IEEE; 2020:1-3. DOI: 10.1109/NSS/MIC42677.2020.9507903
24. Arabi H, Zeng G, Zheng G, et al. Novel adversarial semantic structure deep learning for MRI-guided attenuation correction in brain PET/MRI. *European journal of nuclear medicine and molecular imaging* 2019;46:2746-2759. DOI: 10.1007/s00259-019-04380-x
25. Armanious K, Jiang C, Abdulatif S, et al. Unsupervised medical image translation using cycle-MedGAN. *2019 27th European signal processing conference (EUSIPCO)*: IEEE; 2019:1-5. DOI: 10.23919/EUSIPCO.2019.8902799
26. Armanious K, Jiang C, Fischer M, et al. MedGAN: Medical image translation using GANs. *Comput Med Imaging Graph* 2020;79:101684. DOI: 10.1016/j.compmedimag.2019.101684
27. Bazangani F, Richard FJ, Ghattas B, et al. FDG-PET to T1 Weighted MRI Translation with 3D Elicit Generative Adversarial Network (E-GAN). *Sensors* 2022;22:4640. DOI: 10.3390/s22124640
28. Bharti V, Biswas B, Shukla KK. Qemcgan: quantized evolutionary gradient aware multiobjective cyclic gan for medical image translation. *IEEE Journal of Biomedical and Health Informatics* 2023;DOI: 10.1109/JBHI.2023.3263434
29. Blanc-Durand P, Khalife M, Sgard B, et al. Attenuation correction using 3D deep convolutional neural network for brain 18F-FDG PET/MR: Comparison with Atlas, ZTE and CT based attenuation correction. *PLoS one* 2019;14:e0223141. DOI: 10.1371/journal.pone.0223141
30. Bourbonne V, Jaouen V, Hognon C, et al. Dosimetric validation of a GAN-based pseudo-CT generation for MRI-only stereotactic brain radiotherapy. *Cancers* 2021;13:1082. DOI: 10.3390/cancers13051082
31. Cao G, Liu S, Mao H, et al. Improved CycleGAN for MR to CT synthesis. *2021 6th International Conference on Intelligent Informatics and Biomedical Sciences (ICIIBMS)*; 2021:205-208. DOI: 10.1109/ICIIBMS52876.2021.9651571
32. Chen X, Kuang T, Deng H, et al. Dual adversarial attention mechanism for unsupervised domain adaptive medical image segmentation. *IEEE Transactions on Medical Imaging* 2022;41:3445-3453. DOI: 10.1109/TMI.2022.3186698
33. Choi H, Lee DS. Generation of Structural MR Images from Amyloid PET: Application to MR-Less Quantification. *J Nucl Med* 2018;59:1111-1117. DOI: 10.2967/jnumed.117.199414
34. Dinkla AM, Wolterink JM, Maspero M, et al. MR-only brain radiation therapy: dosimetric evaluation of synthetic CTs generated by a dilated convolutional neural network. *International Journal of Radiation Oncology* Biology* Physics* 2018;102:801-812. DOI: 10.1016/j.ijrobp.2018.05.058
35. Dovletov G, Pham DD, Lörcks S, et al. Grad-CAM Guided U-Net for MRI-based Pseudo-CT Synthesis. *2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC)*: IEEE; 2022:2071-2075. DOI: 10.1109/EMBC48229.2022.9871994
36. Emami H, Dong M, Glide-Hurst CK. Attention-guided generative adversarial network to address atypical anatomy in synthetic CT generation. *2020 IEEE 21st international conference on information reuse and integration for data science (IRI)*: IEEE; 2020:188-193. DOI: 10.1109/IRI49571.2020.00034
37. Emami H, Dong M, Nejad-Davarani SP, et al. Generating synthetic CTs from magnetic resonance images using generative adversarial networks. *Medical physics* 2018;45:3627-3636. DOI: 10.1002/mp.13047
38. Estakhraji SIZ, Pirasteh A, Bradshaw T, et al. On the effect of training database size for MR-based synthetic CT generation in the head. *Computerized Medical Imaging and Graphics* 2023;107:102227. DOI: 10.1016/j.compmedimag.2023.102227
39. Feng E, Qin P, Chai R, et al. MRI Generated From CT for Acute Ischemic Stroke Combining Radiomics and Generative Adversarial Networks. *IEEE Journal of Biomedical and Health Informatics* 2022;26:6047-6057. DOI: 10.1109/JBHI.2022.3205961
40. Garzón G, Gomez S, Mantilla D, et al. A deep CT to MRI unpaired translation that preserve ischemic stroke lesions. *2022 44th Annual International Conference of the IEEE Engineering in Medicine & Biology Society (EMBC)*: IEEE; 2022:2708-2711. DOI: 10.1109/EMBC48229.2022.9871154
41. Gholamiankhan F, Mostafapour S, Arabi H. Deep learning-based synthetic CT generation from MR images: comparison of generative adversarial and residual neural networks. *International Journal of Radiation Research* 2022;20:121-130. DOI: 10.52547/ijrr.20.1.19
42. Gong K, Yang J, Larson PE, et al. MR-based attenuation correction for brain PET using 3-D cycle-consistent adversarial network. *IEEE Transactions on Radiation and Plasma Medical Sciences* 2020;5:185-192. DOI: 10.1109/TRPMS.2020.3006844

43. Gu X, Zhang Y, Zeng W, et al. Cross-modality image translation: CT image synthesis of MR brain images using multi generative network with perceptual supervision. *Computer Methods and Programs in Biomedicine* 2023;237:107571. DOI: 10.1016/j.cmpb.2023.107571
44. Gu Y, Zheng Q. A transfer deep generative adversarial network model to synthetic brain ct generation from MR images. *Wireless Communications and Mobile Computing* 2021;2021DOI: 10.1155/2021/9979606
45. Gupta D, Kim M, Vineberg KA, et al. Generation of synthetic CT images from MRI for treatment planning and patient positioning using a 3-channel U-net trained on sagittal images. *Frontiers in oncology* 2019;9:964. DOI: 10.3389/fonc.2019.00964
46. Gutierrez A, Tuladhar A, Wilms M, et al. Lesion-preserving unpaired image-to-image translation between MRI and CT from ischemic stroke patients. *International Journal of Computer Assisted Radiology and Surgery* 2023;18:827-836. DOI: 10.1007/s11548-022-02828-4
47. Han R, Jones C, Wu P, et al. Deformable registration of MRI to intraoperative cone-beam CT of the brain using a joint synthesis and registration network. *Medical Imaging 2022: Image-Guided Procedures, Robotic Interventions, and Modeling*: SPIE; 2022:30-36. DOI: 10.1117/12.2611783
48. Han R, Jones C, Ketcha M, et al. Deformable MR-CT image registration using an unsupervised synthesis and registration network for neuro-endoscopic surgery. *Medical Imaging 2021: Image-Guided Procedures, Robotic Interventions, and Modeling*: SPIE; 2021:335-342. DOI: 10.1117/12.2581567
49. Han X. MR-based synthetic CT generation using a deep convolutional neural network method. *Med Phys* 2017;44:1408-1419. DOI: 10.1002/mp.12155
50. Hashimoto F, Ito M, Ote K, et al. Deep learning-based attenuation correction for brain PET with various radiotracers. *Annals of Nuclear Medicine* 2021;35:691-701. DOI: 10.1007/s12149-021-01611-w
51. Hu S, Lei B, Wang S, et al. Bidirectional mapping generative adversarial networks for brain MR to PET synthesis. *IEEE Transactions on Medical Imaging* 2021;41:145-157. DOI: 10.1109/TMI.2021.3107013
52. Hu S, Yuan J, Wang S. Cross-modality synthesis from MRI to PET using adversarial U-net with different normalization. *2019 international conference on medical imaging physics and engineering (ICMIPE)*: IEEE; 2019:1-5. DOI: 10.1109/ICMIPE47306.2019.9098219
53. Huo Y, Xu Z, Moon H, et al. Synseg-net: Synthetic segmentation without target modality ground truth. *IEEE transactions on medical imaging* 2018;38:1016-1025. DOI: 10.1109/TMI.2018.2876633
54. Hussein R, Zhao MY, Shin D, et al. Multi-task Deep Learning for Cerebrovascular Disease Classification and MRI-to-PET Translation. *2022 26th International Conference on Pattern Recognition (ICPR)*: IEEE; 2022:4306-4312. DOI: 10.1109/ICPR56361.2022.9956549
55. Jabbarpour A, Mahdavi SR, Sadr AV, et al. Unsupervised pseudo CT generation using heterogenous multicentric CT/MR images and CycleGAN: Dosimetric assessment for 3D conformal radiotherapy. *Computers in biology and medicine* 2022;143:105277. DOI: 10.1016/j.combiomed.2022.105277
56. Jang H, Liu F, Zhao G, et al. Deep learning based MRAC using rapid ultrashort echo time imaging. *Medical physics* 2018;45:3697-3704. DOI: 10.1002/mp.12964
57. Jiao J, Namburete AI, Papageorghiou AT, et al. Self-supervised ultrasound to MRI fetal brain image synthesis. *IEEE Transactions on Medical Imaging* 2020;39:4413-4424. DOI: 10.1109/TMI.2020.3018560
58. Jin C-B, Kim H, Liu M, et al. Deep CT to MR Synthesis Using Paired and Unpaired Data. *Sensors* 2019;19:2361. DOI: 10.3390/s19102361
59. Jin CB, Kim H, Jung W, et al. CT-Based MR Synthesis Using Adversarial Cycle-Consistent Networks with Paired Data Learning. *2018 11th International Congress on Image and Signal Processing, BioMedical Engineering and Informatics (CISP-BMEI)*; 2018:1-6. DOI: 10.1109/CISP-BMEI.2018.8633074
60. Kazemifar S, Barragán Montero AM, Souris K, et al. Dosimetric evaluation of synthetic CT generated with GANs for MRI-only proton therapy treatment planning of brain tumors. *Journal of applied clinical medical physics* 2020;21:76-86. DOI: 10.1002/acm2.12856
61. Kazemifar S, McGuire S, Timmerman R, et al. MRI-only brain radiotherapy: Assessing the dosimetric accuracy of synthetic CT images generated using a deep learning approach. *Radiotherapy and Oncology* 2019;136:56-63. DOI: 10.1016/j.radonc.2019.03.026
62. Kearney V, Ziemer BP, Perry A, et al. Attention-aware discrimination for MR-to-CT image translation using cycle-consistent generative adversarial networks. *Radiology Artificial Intelligence* 2020;2DOI: 10.1148/ryai.2020190027
63. Kläser K, Varsavsky T, Markiewicz P, et al. Imitation learning for improved 3D PET/MR attenuation correction. *Medical image analysis* 2021;71:102079. DOI: 10.1016/j.media.2021.102079
64. Klaser K, Borges P, Shaw R, et al. A multi-channel uncertainty-aware multi-resolution network for MR to CT synthesis. *Applied Sciences* 2021;11:1667. DOI: 10.3390/app11041667

65. Koh H, Park TY, Chung YA, et al. Acoustic simulation for transcranial focused ultrasound using GAN-based synthetic CT. *IEEE Journal of Biomedical and Health Informatics* 2021;26:161-171. DOI: 10.1109/JBHI.2021.3103387
66. Koike Y, Akino Y, Sumida I, et al. Feasibility of synthetic computed tomography generated with an adversarial network for multi-sequence magnetic resonance-based brain radiotherapy. *Journal of radiation research* 2020;61:92-103. DOI: 10.1093/jrr/trz063
67. Ladefoged CN, Marner L, Hindsholm A, et al. Deep learning based attenuation correction of PET/MRI in pediatric brain tumor patients: evaluation in a clinical setting. *Frontiers in neuroscience* 2019;12:1005. DOI: 10.3389/fnins.2018.01005
68. Lan H, Initiative ADN, Toga AW, et al. Three-dimensional self-attention conditional GAN with spectral normalization for multimodal neuroimaging synthesis. *Magnetic resonance in medicine* 2021;86:1718-1733. DOI: 10.1002/mrm.28819
69. Lei Y, Wang T, Liu Y, et al. MRI-based synthetic CT generation using deep convolutional neural network. *Medical Imaging 2019: Image Processing*: SPIE; 2019:716-721. DOI: 10.1117/12.2512549
70. Lei Y, Harms J, Wang T, et al. MRI-only based synthetic CT generation using dense cycle consistent generative adversarial networks. *Medical physics* 2019;46:3565-3581. DOI: 10.1002/mp.13617
71. Li G, Bai L, Zhu C, et al. A novel method of synthetic CT generation from MR images based on convolutional neural networks. *2018 11th International Congress on Image and Signal Processing, BioMedical Engineering and Informatics (CISP-BMEI)*: IEEE; 2018:1-5. DOI: 10.1109/CISP-BMEI.2018.8633142
72. Li W, Li Y, Qin W, et al. Magnetic resonance image (MRI) synthesis from brain computed tomography (CT) images based on deep learning methods for magnetic resonance (MR)-guided radiotherapy. *Quantitative imaging in medicine and surgery* 2020;10:1223. DOI: 10.21037/qims-19-885
73. Li Y, Wei J, Qi Z, et al. Synthesize CT from paired MRI of the same patient with patch-based generative adversarial network. *Medical Imaging 2020: Computer-Aided Diagnosis*: SPIE; 2020:919-924. DOI: 10.1117/12.2551285
74. Li Y, Li W, Xiong J, et al. Comparison of supervised and unsupervised deep learning methods for medical image synthesis between computed tomography and magnetic resonance images. *BioMed Research International* 2020;2020DOI: 10.1155/2020/5193707
75. Liu F, Jang H, Kijowski R, et al. Deep learning MR imaging-based attenuation correction for PET/MR imaging. *Radiology* 2018;286:676-684. DOI: 10.1148/radiol.2017170700
76. Liu F, Yadav P, Baschnagel AM, et al. MR-based treatment planning in radiation therapy using a deep learning approach. *Journal of applied clinical medical physics* 2019;20:105-114. DOI: 10.1002/acm2.12554
77. Liu H, Nai Y-H, Saridin F, et al. Improved amyloid burden quantification with nonspecific estimates using deep learning. *European Journal of Nuclear Medicine and Molecular Imaging* 2021;48:1842-1853. DOI: 10.1007/s00259-020-05131-z
78. Liu H, Nai Y-H, Chen C, et al. Deep Learning-Based Estimation of Non-Specific Uptake in Amyloid-PET Images from Structural MRI for Improved Quantification of Amyloid Load in Alzheimer's Disease. *2020 IEEE 33rd International Symposium on Computer-Based Medical Systems (CBMS)*: IEEE; 2020:573-578. DOI: 10.1109/CBMS49503.2020.00114
79. Liu M, Zou W, Wang W, et al. Multi-Conditional Constraint Generative Adversarial Network-Based MR Imaging from CT Scan Data. *Sensors (Basel)* 2022;22DOI: 10.3390/s22114043
80. Liu X, Emami H, Nejad-Davarani SP, et al. Performance of deep learning synthetic CTs for MR-only brain radiation therapy. *Journal of applied clinical medical physics* 2021;22:308-317. DOI: 10.1002/acm2.13139
81. Maspero M, Bentvelzen LG, Savenije MH, et al. Deep learning-based synthetic CT generation for paediatric brain MR-only photon and proton radiotherapy. *Radiotherapy and Oncology* 2020;153:197-204. DOI: 10.1016/j.radonc.2020.09.029
82. Nehra R, Pal A, Baranidharan B. Radiological image synthesis using cycle-consistent generative adversarial network. *Proceedings of International Conference on Recent Trends in Computing: ICRTC 2021*: Springer; 2022:391-402. DOI: 10.1007/978-981-16-7118-0_34
83. Neppi S, Landry G, Kurz C, et al. Evaluation of proton and photon dose distributions recalculated on 2D and 3D Unet-generated pseudoCTs from T1-weighted MR head scans. *Acta Oncologica* 2019;58:1429-1434. DOI: 10.1080/0284186X.2019.1630754
84. Nie D, Trullo R, Lian J, et al. Medical image synthesis with context-aware generative adversarial networks. *International conference on medical image computing and computer-assisted intervention*: Springer; 2017:417-425. DOI: 10.1007/978-3-319-66179-7_48

85. Nie D, Trullo R, Lian J, et al. Medical image synthesis with deep convolutional adversarial networks. *IEEE Transactions on Biomedical Engineering* 2018;65:2720-2730. DOI: 10.1109/TBME.2018.2814538
86. Nijskens L, van den Berg CA, Verhoeff JJ, et al. Exploring contrast generalisation in deep learning-based brain MRI-to-CT synthesis. *Physica Medica* 2023;112:102642. DOI: 10.1016/j.ejmp.2023.102642
87. Pan Y, Liu M, Lian C, et al. Synthesizing Missing PET from MRI with Cycle-consistent Generative Adversarial Networks for Alzheimer's Disease Diagnosis. Cham: Springer International Publishing; 2018:455-463. DOI: 10.1007/978-3-030-00931-1_52
88. Prokopenko D, Stadelmann JV, Schulz H, et al. Unpaired synthetic image generation in radiology using gans. *Artificial Intelligence in Radiation Therapy: First International Workshop, AIRT 2019, Held in Conjunction with MICCAI 2019, Shenzhen, China, October 17, 2019, Proceedings I*: Springer; 2019:94-101. DOI: 10.1007/978-3-030-32486-5_12
89. Qin J, Tang Y, Wang B. Regional 18F-fluoromisonidazole PET images generated from multiple advanced MR images using neural networks in glioblastoma. *Medicine* 2022;101DOI: 10.1097/MD.0000000000029572
90. Ranjan A, Lalwani D, Misra R. GAN for synthesizing CT from T2-weighted MRI data towards MR-guided radiation treatment. *Magnetic Resonance Materials in Physics, Biology and Medicine* 2022;35:449-457. DOI: 10.1007/s10334-021-00974-5
91. Reinhold JC, He Y, Han S, et al. Validating uncertainty in medical image translation. *2020 IEEE 17th International Symposium on Biomedical Imaging (ISBI)*: IEEE; 2020:95-98. DOI: 10.1109/ISBI45749.2020.9098543
92. Reinhold J, He Y, Han S, et al. *Finding novelty with uncertainty*. SPIE; 2020:MI. DOI: 10.1117/12.2549341
93. Rubin J, Abulnaga SM. CT-To-MR Conditional Generative Adversarial Networks for Ischemic Stroke Lesion Segmentation. *2019 IEEE International Conference on Healthcare Informatics (ICHI)*; 2019:1-7. DOI: 10.1109/ICHI.2019.8904574
94. Sanaat A, Shiri I, Ferdowsi S, et al. Robust-Deep: a method for increasing brain imaging datasets to improve deep learning models' performance and robustness. *Journal of Digital Imaging* 2022;35:469-481. DOI: 10.14338/IJPT-19-00062.1
95. Shafai-Erfani G, Lei Y, Liu Y, et al. MRI-based proton treatment planning for base of skull tumors. *International journal of particle therapy* 2019;6:12-25. DOI: 10.14338/IJPT-19-00062.1
96. Singh M, Pahl E, Wang S, et al. Accurate estimation of total intracranial volume in MRI using a multi-task image-to-image translation network. *Medical Imaging 2021: Image Processing*: SPIE; 2021:110-117. DOI: 10.1117/12.2582264
97. Soltanpour M, Yousefnezhad M, Greiner R, et al. Using temporal GAN to translate the current CTP scan to follow-up MRI, for predicting final acute ischemic stroke lesions. *Medical Imaging 2023: Computer-Aided Diagnosis*: SPIE; 2023:800-805. DOI: 10.1117/12.2654069
98. Spuhler KD, Gardus J, Gao Y, et al. Synthesis of patient-specific transmission data for PET attenuation correction for PET/MRI neuroimaging using a convolutional neural network. *Journal of nuclear medicine* 2019;60:555-560. DOI: 10.2967/jnumed.118.214320
99. Stimpel B, Syben C, Würfl T, et al. *Projection image-to-image translation in hybrid x-ray/MR imaging*. SPIE; 2019:MI. DOI: 10.1117/12.2512195
100. Sun B, Jia S, Jiang X, et al. Double U-Net CycleGAN for 3D MR to CT image synthesis. *International Journal of Computer Assisted Radiology and Surgery* 2023;18:149-156. DOI: 10.1007/s11548-022-02732-x
101. Sun H, Mehta R, Zhou HH, et al. Dual-glow: Conditional flow-based generative model for modality transfer. *Proceedings of the IEEE/CVF International Conference on Computer Vision*; 2019:10611-10620. DOI: 10.1109/iccv.2019.01071
102. Takamiya K, Iwamoto Y, Nonaka M, et al. CT Brain Image Synthesization from MRI Brain Images Using CycleGAN. *2023 IEEE International Conference on Consumer Electronics (ICCE)*: IEEE; 2023:1-4. DOI: 10.1109/ICCE56470.2023.10043572
103. Takita H, Matsumoto T, Tatekawa H, et al. AI-based virtual synthesis of methionine PET from contrast-enhanced MRI: development and external validation study. *Radiology* 2023;308:e223016. DOI: 10.1148/radiol.223016
104. Tao L, Fisher J, Anaya E, et al. Pseudo CT image synthesis and bone segmentation from MR images using adversarial networks with residual blocks for MR-based attenuation correction of brain PET data. *IEEE Transactions on Radiation and Plasma Medical Sciences* 2020;5:193-201. DOI: 10.1109/TRPMS.2020.2989073

105. Wang C, Uh J, Merchant TE, et al. Facilitating MR-Guided Adaptive Proton Therapy in Children Using Deep Learning-Based Synthetic CT. *International Journal of Particle Therapy* 2022;8:11-20. DOI: 10.14338/IJPT-20-00099.1
106. Wang C, Uh J, Patni T, et al. Toward MR-only proton therapy planning for pediatric brain tumors: Synthesis of relative proton stopping power images with multiple sequence MRI and development of an online quality assurance tool. *Medical Physics* 2022;49:1559-1570. DOI: 10.1002/mp.15479
107. Wang C-C, Wu P-H, Lin G, et al. Magnetic Resonance-Based Synthetic Computed Tomography Using Generative Adversarial Networks for Intracranial Tumor Radiotherapy Treatment Planning. *Journal of personalized medicine* 2022;12:361. DOI: 10.3390/jpm12030361
108. Wang J, Yan B, Wu X, et al. Development of an unsupervised cycle contrastive unpaired translation network for MRI-to-CT synthesis. *Journal of Applied Clinical Medical Physics* 2022;23:e13775. DOI: 10.1002/acm2.13775
109. Wang Jiangtao WX, Yan Bing, Zhu Lei, Yang Yidong. Mutual information-based contrastive learning for the generation of pseudo-CT images of the head from magnetic resonance imaging. *Chinese Journal of Radiological Medicine and Protection* 2022;42DOI: 10.3760/cma.j.cn112271-20210810-00318
110. Jiangtao W, Xinhong W, Xiao J, et al. MRI to CT synthesis using contrastive learning. *2021 IEEE International Conference on Medical Imaging Physics and Engineering (ICMIPE)*: IEEE; 2021:1-5. DOI: 10.1109/ICMIPE53131.2021.9698888
111. Wang J, Wu QJ, Pourpanah F. Dc-cyclegan: bidirectional ct-to-mr synthesis from unpaired data. *Computerized Medical Imaging and Graphics* 2023:102249. DOI: 10.1016/j.compmedimag.2023.102249
112. Wei W, Poirion E, Bodini B, et al. Predicting PET-derived demyelination from multimodal MRI using sketcher-refiner adversarial training for multiple sclerosis. *Medical image analysis* 2019;58:101546. DOI: 10.1016/j.media.2019.101546
113. Wolterink JM, Dinkla AM, Savenije MH, et al. Deep MR to CT synthesis using unpaired data. *Simulation and Synthesis in Medical Imaging: Second International Workshop, SASHIMI 2017, Held in Conjunction with MICCAI 2017, Québec City, QC, Canada, September 10, 2017, Proceedings 2*: Springer; 2017:14-23. DOI: 10.1007/978-3-319-68127-6_2
114. Xiang L, Wang Q, Nie D, et al. Deep embedding convolutional neural network for synthesizing CT image from T1-Weighted MR image. *Medical image analysis* 2018;47:31-44. DOI: 10.1016/j.media.2018.03.011
115. Xu R, Zhang Y, Ye X, et al. Unsupervised MR to CT Image Translation Exploiting Multi-scale and Contextual Cues. *Innovation in Medicine and Healthcare*: Springer; 2022:161-170. DOI: 10.1007/978-981-19-3440-7_15
116. Yang H, Qian P, Fan C. An indirect multimodal image registration and completion method guided by image synthesis. *Computational and Mathematical Methods in Medicine* 2020;2020DOI: 10.1155/2020/2684851
117. Yang H, Sun J, Carass A, et al. Unsupervised MR-to-CT synthesis using structure-constrained CycleGAN. *IEEE transactions on medical imaging* 2020;39:4249-4261. DOI: 10.1109/TMI.2020.3015379
118. Zhang J, He X, Qing L, et al. BPGAN: Brain PET synthesis from MRI using generative adversarial network for multi-modal Alzheimer's disease diagnosis. *Computer Methods and Programs in Biomedicine* 2022;217:106676. DOI: 10.1016/j.cmpb.2022.106676
119. Zhao S, Geng C, Guo C, et al. SARU: A self-attention ResUNet to generate synthetic CT images for MR-only BNCT treatment planning. *Medical Physics* 2022DOI: 10.1002/mp.15986